Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LARRY EDWARD CLARK

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1780659508
CMS profile
35882
Location
LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$302,993.31

410 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 9; records 101–150 of 410 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LARRY EDWARD CLARK

NPI 1780659508 · CMS profile ID 35882

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

LYNCHBURG, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 9; records 101–150 of 410 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780659508?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LARRY EDWARD CLARK, NPI 1780659508, CMS profile ID 35882. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 410 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780659508?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LARRY EDWARD CLARK, NPI 1780659508, CMS profile ID 35882. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 410 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780659508?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LARRY EDWARD CLARK, NPI 1780659508, CMS profile ID 35882, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 9; records 101–150 of 410 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1780659508?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

410 matching records · $302,993.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 410 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 410.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Phathom Pharmaceuticals, Inc. $2,580.0010/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050551 CMS
Phathom Pharmaceuticals, Inc. $1,290.0010/03/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050553 CMS
ABBVIE INC. $54.2710/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180984 CMS
ABBVIE INC. $8.5010/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180986 CMS
ABBVIE INC. $201.0010/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180988 CMS
ABBVIE INC. $54.2710/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180990 CMS
ABBVIE INC. $164.8210/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180992 CMS
Medtronic, Inc. $21.8910/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119482288 CMS
Phathom Pharmaceuticals, Inc. $13.5610/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050549 CMS
Phathom Pharmaceuticals, Inc. $124.0710/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050545 CMS
Phathom Pharmaceuticals, Inc. $319.4310/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050547 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.4609/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137514463 CMS
Janssen Biotech, Inc. $59.3309/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078803998 CMS
Janssen Biotech, Inc. $38.1509/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078804135 CMS
Janssen Biotech, Inc. $38.9309/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078804299 CMS
Janssen Biotech, Inc. $537.9509/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078803622 CMS
Janssen Biotech, Inc. $636.6209/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078803963 CMS
Janssen Biotech, Inc. $149.8709/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078804175 CMS
Ardelyx, Inc. $15.0709/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146676046 CMS
PFIZER INC. $352.8509/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132027009 CMS
Phathom Pharmaceuticals, Inc. $3,010.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050543 CMS
AIMMUNE THERAPEUTICS, INC. $19.3609/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147008956 CMS
PFIZER INC. $3.0609/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131975811 CMS
Phathom Pharmaceuticals, Inc. $90.7209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050541 CMS
Intercept Pharmaceuticals, Inc. $13.9609/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113637170 CMS
Phathom Pharmaceuticals, Inc. $124.1609/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050539 CMS
ABBVIE INC. $30.8909/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103477295 CMS
ABBVIE INC. $29.4109/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103477291 CMS
ABBVIE INC. $125.0009/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103477293 CMS
ABBVIE INC. $504.1309/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104180982 CMS
PFIZER INC. $4,275.0009/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131440958 CMS
PFIZER INC. $223.7809/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131440962 CMS
PFIZER INC. $258.4809/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131445705 CMS
Phathom Pharmaceuticals, Inc. $253.2609/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050537 CMS
Celgene Corporation $11.6209/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101099346 CMS
Phathom Pharmaceuticals, Inc. $15.7009/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050535 CMS
Janssen Biotech, Inc. $35.1809/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078803764 CMS
PFIZER INC. $631.7509/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132027007 CMS
Phathom Pharmaceuticals, Inc. $100.0009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050531 CMS
Phathom Pharmaceuticals, Inc. $121.4409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151050533 CMS
Janssen Biotech, Inc. $18.5209/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078804196 CMS
PFIZER INC. $104.0009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131445709 CMS
Lilly USA, LLC $32.2509/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135083304 CMS
Lilly USA, LLC $24.0009/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135124448 CMS
Lilly USA, LLC $23.6009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135141455 CMS
Lilly USA, LLC $75.0409/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135145859 CMS
PFIZER INC. $20.0009/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132017454 CMS
PFIZER INC. $75.0009/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132024829 CMS
PFIZER INC. $108.4909/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132024831 CMS
PFIZER INC. $161.9709/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132024833 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $216,318.20 461
PY2020 $45,476.41 91
PY2021 $85,349.50 152
PY2022 $174,587.77 276
PY2023 $156,584.54 245
PY2024 $302,993.31 410
PY2025 $265,541.45 316

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,292,443.20 72
PY2024 Principal investigator $1,742,907.88 105
PY2023 Principal investigator $2,180,116.03 150
PY2022 Principal investigator $222,571.64 60
PY2021 Recipient $2,500.00 1
PY2021 Principal investigator $159,956.79 25
PY2020 Principal investigator $286,858.90 90
PY2019 Recipient $1,359.54 2
PY2019 Principal investigator $385,776.82 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,563.00 12/11/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051212
Principal investigator 1 Genentech, Inc. $100,575.00 12/01/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608172
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,563.00 11/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051210
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42,841.25 11/06/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235997221
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $68.90 10/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223286465
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $689.00 10/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223286467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $689.00 10/08/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223286469
Principal investigator 1 Genentech, Inc. $34,138.00 09/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608164
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,126.00 09/18/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051208
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,563.00 07/31/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051206
Principal investigator 1 Genentech, Inc. $493,900.00 07/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608160
Principal investigator 1 Genentech, Inc. $462,300.00 07/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,108.00 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282072
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,108.00 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282074
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,930.00 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282076
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35,200.10 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282082
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,807.60 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282094
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,930.00 07/02/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282096
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $96,449.06 06/05/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235997219
Principal investigator 1 Genentech, Inc. $1,352.00 05/28/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608148
Principal investigator 1 Genentech, Inc. $67,918.00 04/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608144
Principal investigator 1 Genentech, Inc. $1,114.00 04/25/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608155
Principal investigator 1 Celgene Corporation $90,509.86 04/10/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306112
Principal investigator 1 Genentech, Inc. $1,114.00 04/04/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608152
Principal investigator 1 Genentech, Inc. $42,724.00 03/26/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608119
Principal investigator 1 PFIZER INC. $3,282.00 03/19/2025 Non-covered Recipient Entity
Gastroenterology Associates of Central Virginia Inc
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775775
Principal investigator 1 PFIZER INC. $2,085.70 03/19/2025 Non-covered Recipient Entity
Gastroenterology Associates of Central Virginia Inc
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228777340
Principal investigator 1 Celgene Corporation $42,556.21 03/14/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306010
Principal investigator 1 Genentech, Inc. $55,700.00 03/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608095
Principal investigator 1 Genentech, Inc. $5,570.00 03/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608125
Principal investigator 1 Genentech, Inc. $13,368.00 02/21/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608140
Principal investigator 1 Genentech, Inc. $24,508.00 02/12/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608136
Principal investigator 1 Celgene Corporation $14,835.00 02/07/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222306058
Principal investigator 1 Genentech, Inc. $18,938.00 02/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608099
Principal investigator 1 Genentech, Inc. $21,166.00 02/05/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608133
Principal investigator 1 Celgene Corporation $1,728.05 01/29/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 1222306186
Principal investigator 1 Genentech, Inc. $17,824.00 01/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608114
Principal investigator 1 Genentech, Inc. $5,570.00 01/24/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608122
Principal investigator 1 PFIZER INC. $2,500.00 01/24/2025 Non-covered Recipient Entity
Gastroenterology Associates of Central Virginia Inc
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775889
Principal investigator 1 PFIZER INC. $1,500.00 01/24/2025 Non-covered Recipient Entity
Gastroenterology Associates of Central Virginia Inc
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228786898
Principal investigator 1 Genentech, Inc. $37,876.00 01/22/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608129
Principal investigator 1 Genentech, Inc. $46,013.00 01/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608102
Principal investigator 1 Genentech, Inc. $91,350.00 01/17/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608105
Principal investigator 1 Celgene Corporation $7,240.00 01/13/2025 Non-covered Recipient Entity
Gastroenterology Associates Of Central Virginia
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222306018
Principal investigator 1 Genentech, Inc. $44,560.00 01/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608092
Principal investigator 1 Genentech, Inc. $31,192.00 01/13/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211608110
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,000.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273429
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $230.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273431
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $161,550.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273433
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,400.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273435
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,350.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273437
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,460.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,015.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273443
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $101.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273445
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23.47 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,400.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273451
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,195.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,250.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273475
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,280.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $540.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273481
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,570.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,885.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,016.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,525.00 01/03/2025 Non-covered Recipient Entity
GASTROENTEROLOGY ASSOCIATES OF CENTRAL VIRGINIA INC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223273491